Showing results (971-980 of 991) with videos related to

Sort By:
Pageof 100
Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
The Lancet. Oncology|June 17, 2020
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort studyMarina Chiara Garassino, Jennifer G Whisenant, Li-Ching Huang, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
Lung Cancer (Amsterdam, Netherlands)|November 1, 2020
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY studyMelissa Bersanelli, Sebastiano Buti, Diana Giannarelli, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.
Thoracic Cancer|February 2, 2021
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter studyAlessio Cortellini, Andrea De Giglio, Katia Cannita, et al.
Prostate Cancer and Prostatic Diseases|May 28, 2026
EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progressionFabio Turco, Silke Gillessen, Giuseppe Salfi, et al.
Journal for Immunotherapy of Cancer|April 8, 2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapyAlessio Cortellini, Massimo Di Maio, Olga Nigro, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2021
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapySebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
The Oncologist|May 20, 2026
Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy CombinationsSara Elena Rebuzzi, Aruni Ghose, Sarah Rudman, et al.
Pageof 100